前药
免疫系统
顺铂
免疫疗法
常用化疗药物
化疗
药理学
癌症研究
获得性免疫系统
医学
免疫学
内科学
作者
Daniel Yuan Qiang Wong,Charmian Hui Fang Yeo,Wee Han Ang
标识
DOI:10.1002/anie.201402879
摘要
There is growing consensus that the clinical therapeutic efficacy of some chemotherapeutic agents depends on their off-target immune-modulating effects. Pt anticancer drugs have previously been identified to be potent immunomodulators of both the innate and the adaptive immune system. Nevertheless, there has been little development in the rational design of Pt-based chemotherapeutic agents to exploit their immune-activating capabilities. The FPR1/2 formyl peptide receptors are highly expressed in immune cells, as well as in many metastatic cancers. Herein, we report a rationally designed multimodal Pt(IV) prodrug containing a FPR1/2-targeting peptide that combines chemotherapy with immunotherapy to achieve therapeutic synergy and demonstrate the feasibility of this approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI